RedHill Biopharma (RDHL) announced that the New York Supreme Court’s summary judgment in favor of RedHill against Kukbo Co. is now final and eligible for enforcement and foreign recognition, with no further appeal permissible following expiry of the appeal period. The Court has awarded more than $10.5M in total to RedHill, comprised of the main judgment of approximately $8.6M, now final and eligible for enforcement, and the award for legal fees and expenses of approximately $1.9M (both include the principal amounts and accrued interest, to date) which remains subject to appeal until March 13, 2026. 9% annual statutory interest continues to accrue on both awards. In addition, RedHill has secured a Korean court attachment grant against Kukbo aimed at preventing Kukbo from disposing of assets prior to judgment enforcement.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RDHL:
- RedHill Biopharma Appeals Nasdaq Delisting Notice After Equity Boost
- RedHill Biopharma Amends Purchase Agreement with Alumni Capital
- RedHill Biopharma Secures $4 Million Investment and U.S. Partnership for Talicia
- RedHill Biopharma signs strategic partnership with Cumberland
- RedHill Biopharma Secures $1.8 Million Middle East Deal for Talicia